Blog

Aaron Goodman: This is nice paper that goes over differentiation syndrome associated with IDH1/2 inhibitors

Photo taken from aacrjournals.org

Apr 26, 2024, 06:18

Aaron Goodman: This is nice paper that goes over differentiation syndrome associated with IDH1/2 inhibitors

Aaron Goodman shared on X:

“This is nice paper that goes over differentiation syndrome associated with IDH1/2 inhibitors. Useful clinical stuff like time to onset and more.”

Additional information.
Source: Aaron Goodman/X

Aaron Goodman is a Hematologist/ Oncologist and an Associate Professor of Medicine at the University of California, San Diego. He is a member of the National Comprehensive Cancer Network (NCCN) guideline committee for both cutaneous NHLs and T-cell NHLs. Dr. Goodman is a well-known physician-scientist, educator, advocate, and social media influencer.

Aaron Goodman cancer Differentiation syndrome IDH1/2 inhibitors National Comprehensive Cancer Network NCCN OncoDaily Oncology University of California

VERITAC-2 Trial Update: Vepdegestrant Meets Primary Endpoint in ESR1-Mutant Breast Cancer

New Paper Alert: HARMONi-2 study of Ivonescimab vs pembrolizumab for PD-L1-positive non-small cell lung cancer

We are thrilled to welcome Dr. Jasmine Kamboj to the OncoDaily Editorial Board!

Oncologist Near Me – Fedro Alessandro Peccatori: Leading Expert in Gynecological Oncology

MATTERHORN trial - FLOT plus durvalumab will become the new standard of care in the preoperative setting for gastroesophageal cancer

Special Coverage